Table 3.
Subgroup analyses for the effect of sarcopenia on PFS in patients with metastases
| Variables | HR | 95% CI | I2 (%) | No. studies | P for interaction | |
|---|---|---|---|---|---|---|
| Regions | < 0.001 | |||||
| Asia | 1.98 | 1.18 to 3.31 | 83.6 | 8 | ||
| Europe | 1.25 | 0.91 to 1.73 | 66.9 | 7 | ||
| Gender | < 0.001 | |||||
| Female ≤ 50% | 1.53 | 1.12 to 2.11 | 79.8 | 12 | ||
| Female > 50% | 1.61 | 1.11 to 2.33 | 21.4 | 4 | ||
| Original cancer type | < 0.001 | |||||
| Gastrointestinal | 1.28 | 0.87 to 1.89 | 79.9 | 6 | ||
| Urologic | 1.57 | 1.02 to 2.41 | 7.3 | 5 | ||
| Endocrine Gland | 2.16 | 1.36 to 3.43 | 0 | 2 | ||
| Breast | 1.51 | 0.60 to 3.80 | 0 | 2 | ||
| Quality assessment | < 0.001 | |||||
| Low risk of bias | 1.56 | 1.10 to 2.21 | 77.1 | 11 | ||
| High risk of bias | 1.59 | 0.96 to 2.62 | 79.2 | 5 | ||
| Type of HR | < 0.001 | |||||
| Univariate | 0.84 | 0.70 to 0.98 | 50.9 | 6 | ||
| Multivariate | 1.01 | 0.81 to 1.22 | 57.8 | 10 |